A detailed history of Walleye Capital LLC transactions in Liquidia Corp stock. As of the latest transaction made, Walleye Capital LLC holds 44,500 shares of LQDA stock, worth $489,945. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,500
Previous 58,000 23.28%
Holding current value
$489,945
Previous $855,000 37.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.96 - $15.71 $2.09 Million - $2.75 Million
-175,096 Reduced 96.17%
6,982 $83,000
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $1.56 Million - $2.29 Million
-137,155 Reduced 42.96%
182,078 $2.69 Million
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $240,695 - $508,505
41,715 Added 15.03%
319,233 $3.84 Million
Q3 2023

Nov 14, 2023

BUY
$6.27 - $8.15 $1.74 Million - $2.26 Million
277,518 New
277,518 $1.76 Million
Q1 2023

May 15, 2023

BUY
$5.72 - $7.91 $759,564 - $1.05 Million
132,791 New
132,791 $917,000
Q3 2022

Nov 14, 2022

SELL
$3.73 - $8.39 $160,695 - $361,457
-43,082 Reduced 36.36%
75,413 $410,000
Q2 2022

Aug 08, 2022

BUY
$3.37 - $7.55 $399,328 - $894,637
118,495 New
118,495 $517,000
Q1 2022

May 16, 2022

SELL
$5.14 - $7.38 $99,978 - $143,548
-19,451 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$2.71 - $5.17 $52,712 - $100,561
19,451 New
19,451 $94,000
Q3 2021

Nov 15, 2021

SELL
$2.28 - $2.95 $29,639 - $38,350
-13,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.51 - $3.11 $32,629 - $40,430
13,000 New
13,000 $37,000
Q4 2020

Feb 16, 2021

SELL
$2.6 - $5.79 $44,769 - $99,698
-17,219 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.34 - $8.28 $74,730 - $142,573
17,219 New
17,219 $85,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.